2.

EGFR-TKIs治疗肺癌脑转移的临床研究

Clinical studies of EGFR-TKIs for brain metastases in lung cancer

Intervention	Published time	Design	EGFR mutation	Number of patients	ORR/DCR（%）	mPFS/OS（mo）
EGFR-TKI: epidermal growth factor receptor-tyrosine kinase inhibitor; ORR: overall response rate; DCR: disease control rate; mPFS: median progress-free survival; OS: overall survival; WBRT: whole-brain radiation therapy; XRT: external-beam radiation therapy; SRS: stereotactic radiosurgery; NR: not reported.
Gefitinib	2004[37]	Prospective single arm phase Ⅱ	Unselected	41	10/27	3/5
	2007[40]	Prospective single arm phase Ⅱ	Adenocarcinoma Asian	40	38/83	9/15
	2009[42]	Prospective single arm phase Ⅱ WBRT+Gefitinib	Adenocarcinoma	21	81/95	10.0/13.0
	2013[38]	Prospective single arm phase Ⅱ	EGFR mutation	41	87.8/97.6	14.5/21.9
Erlotinib	2011[39]	Retrospective Erlotinib±XRT	Unselected	17 EGFR mutation 39 EGFR wild-type	82/100 0/78	11.7/12.9 3.1/5.8
	2013[45]	Prospective single arm phase Ⅱ	Adenocarcinoma or EGFR mutation	48 8 EGFR mutation 15 EGFR wild-type	58.4/75.1 75/87.5 33.3/46.7	9.7/18.9 15.2/37.5 4.4/18.4
	2013[44]	Prospective single arm phase Ⅱ WBRT+Erlotinib	Unselected	40	83/86	8/11.8
	2013[25]	Prospective randomized phase Ⅲ WBRT+SRS vs WBRT+SRS+Erlotinib vs WBRT+SRS+temozomide	Unselected	126	NR	NR 8.1/13.4 4.8/6.1 4.6/6.3
Gefitinib or erlotinib	2009[41]	Prospective single arm phase Ⅱ	Never smoking Adenocarcinoma Asian	23	70/74	7.1/18.8
	2012[43]	Prospective single arm phase Ⅱ	EGFR mutation	28	83/94	6.6/15.9